Equities Analysts Offer Predictions for NKTR Q1 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at Zacks Research issued their Q1 2028 earnings per share estimates for Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 1st. Zacks Research analyst Team expects that the biopharmaceutical company will post earnings of ($3.45) per share for the quarter. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ FY2028 earnings at ($13.82) EPS.

A number of other analysts have also weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Citigroup increased their price objective on Nektar Therapeutics from $102.00 to $123.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of Nektar Therapeutics in a research note on Monday, January 26th. Finally, B. Riley Financial restated a “buy” rating and set a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.13.

Nektar Therapeutics Trading Up 1.7%

Shares of NASDAQ NKTR opened at $76.99 on Thursday. Nektar Therapeutics has a 1-year low of $6.45 and a 1-year high of $78.81. The company has a 50-day moving average of $62.95 and a two-hundred day moving average of $56.53. The company has a market cap of $2.21 billion, a PE ratio of -7.55 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. The firm had revenue of $21.81 million for the quarter, compared to analyst estimates of $10.44 million. Nektar Therapeutics had a negative net margin of 297.07% and a negative return on equity of 386.16%.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the sale, the chief executive officer directly owned 75,489 shares of the company’s stock, valued at $5,510,697. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the sale, the insider directly owned 21,354 shares of the company’s stock, valued at approximately $761,697.18. This trade represents a 15.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 4,470 shares of company stock valued at $181,955. 5.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in shares of Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Compass Wealth Management LLC bought a new stake in Nektar Therapeutics in the third quarter valued at about $88,000. Bessemer Group Inc. increased its holdings in Nektar Therapeutics by 1,741.2% in the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,480 shares during the last quarter. Bayforest Capital Ltd acquired a new position in Nektar Therapeutics in the third quarter valued at about $96,000. Finally, Quarry LP acquired a new position in Nektar Therapeutics in the fourth quarter valued at about $85,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.